- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02765802
A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection (LIMT)
A Phase 2 Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection (LIMT)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Lambda is the pegylated form of interferon lambda-1a (IFN-λ), a conjugate of recombinant human interleukin 29 (rIL-29) and a linear polyethylene glycol (PEG) chain. IFN-λ and interferon alpha (IFN-α) share the common interferon (IFN)-stimulated gene induction pathway that leads to broad-spectrum antiviral activities. Since IFN-α has demonstrated anti-hepatitis delta virus (HDV) activity in patients with chronic hepatitis delta (CHD), it is postulated that pegylated IFN-λ could also induce HDV ribonucleic acid (RNA) decline in patients with CHD. Based on IFN-λ's more limited receptor distribution and previous data from studies involving treatment with IFN-λ in patients with hepatitis B virus (HBV) or hepatitis C virus (HCV), it is postulated that Lambda treatment could be associated with fewer adverse effects than IFN-α treatment. This Phase II study is designed as randomized, open-label study of Lambda 120 or 180 μg subcutaneous (SC) injection weekly for 48 weeks in patients with chronic HDV infection, and the primary objectives of the study are as follows:
- To evaluate the safety and tolerability of treatment with 2 dose levels of Lambda over a 48-week treatment period.
- To evaluate the effect of treatment with 2 different doses of Lambda on HDV RNA levels.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Beersheba, Israel, 84101
- Soroka Medical Center
-
Jerusalem, Israel, 9103102
- Shaare Zedek Medical Center
-
-
-
-
Auckland
-
Grafton, Auckland, New Zealand, 1142
- Auckland City Hospital
-
-
-
-
-
Karachi, Pakistan, 74800
- The Aga Khan University and Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Chronic HDV infection of at least 6 months' duration documented by a positive HDV antibody (Ab) test, detectable and quantifiable HDV RNA by qPCR at study entry
- Serum alanine aminotransferase (ALT) > upper limit of the normal range (ULN) and <10 × ULN at screening
- Electrocardiogram (ECG) demonstrating no acute ischemia or clinically significant abnormality and a QT interval corrected for heart rate (QTcF) <450 ms for male patients and <460 ms for female patients
- Thyroid-stimulating hormone (TSH) and/or free T4 within 0.8 to 1.2 × ULN, or adequately controlled thyroid function as assessed by the investigator.
- Dilated retinal examination ≤1 year before screening
- Female patients of childbearing potential and male patients with partners of childbearing potential must agree to use adequate methods of contraception during the study and through 90 days after the last dose of study medication
Exclusion Criteria:
General Exclusions:
- Participation in a clinical trial with or use of any investigational agent within 30 days before screening, or treatment with interferons (IFNs) or immunomodulators within 12 months before screening
- Previous use of Lambda. Patients who previously participated in a clinical trial of Lambda but are confirmed to have received placebo or other non-Lambda IFNs are allowed.
- History or evidence of any intolerance or hypersensitivity to IFNs or other substances contained in the study medication.
- Female patients who are pregnant or breastfeeding. Male patients must confirm that their female sexual partners are not pregnant.
Exclusions Based on Disease
- Current or previous history of decompensated liver disease (Child-Pugh Class B or C)
- Co-infected with human immunodeficiency virus (HIV) or hepatitis C virus (HCV)
Past history or current evidence of decompensated liver disease, defined as any of the following at screening:
- Bilirubin level ≥ 2.5 mg/dL unless due to Gilbert's disease
- Serum albumin level <3.5 g/dL
- International normalized ratio (INR) ≥1.5
- Alpha fetoprotein ≥100 ng/mL
- Evidence of significant portal hypertension; current presence or history of variceal bleeding, ascites requiring diuretics or paracentesis, or hepatic encephalopathy
Any of the following abnormal laboratory test results at screening:
- Platelet count <90,000 cells/mm^3
- White blood cell count <3,000 cells/mm^3
- Absolute neutrophil count <1,500 cells/mm^3
- Hemoglobin <11 g/dL for women and <12 g/dL for men
- Serum creatinine concentration ≥1.5× ULN
- Confirmed creatinine clearance (CrCl) < 50 mL/min by Cockcroft-Gault
- Evidence of another form of viral hepatitis or another form of liver disease
- History of hepatocellular carcinoma
Patients with any of the following:
- Current eating disorder or alcohol abuse
- Excessive alcohol intake
- In the opinion of the investigator, an alcohol use pattern that will interfere with study conduct
- Drug abuse within the previous 6 months before screening, with the exception of cannabinoids and their derivatives
Prior history or current evidence of any of the following:
- Immunologically mediated disease
- Retinal disorder or clinically relevant ophthalmic disorder
- Any malignancy within 5 years before screening
- Cardiomyopathy or significant ischemic cardiac or cerebrovascular disease.
- Chronic pulmonary disease
- Pancreatitis
- Severe or uncontrolled psychiatric disorder
- Active seizure disorder
- Bone marrow or solid organ transplantation
- Other significant medical condition that may require intervention during the study
Exclusions Based on Concurrent Medication Use
- Therapy with an immunomodulatory agent
- Use of telbivudine
- Current use of heparin or Coumadin
- Received blood products within 30 days before study randomization
- Use of hematologic growth factors within 30 days before study randomization
- Systemic antibiotics, antifungals, or antivirals for treatment of active infection other than HBV within 14 days before study randomization
- Any prescription or herbal product that is not approved by the investigator
- Long-term treatment (> 2 weeks) with agents that have a high risk for nephrotoxicity or hepatotoxicity unless it is approved by the medical monitor
- Receipt of systemic immunosuppressive therapy within 3 months before screening
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lambda 180 μg
Lambda 180 μg once weekly, administered by subcutaneous (SC) injection, for a total of 48 weeks.
|
Other Names:
|
Experimental: Lambda 120 μg
Lambda 120 μg once weekly, administered by subcutaneous (SC) injection, for a total of 48 weeks.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in HDV Viral Load.
Time Frame: Week 48 (end of treatment)
|
To evaluate the safety and tolerability of treatment with 2 dose levels of Lambda over a 48 week treatment period. To evaluate the effect of treatment with 2 different doses of Lambda on hepatitis D virus (HDV) ribonucleic acid (RNA) levels. |
Week 48 (end of treatment)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in HDV Viral Load
Time Frame: Week 72 (end of follow-up)
|
To evaluate the proportion of patients with undetectable HDV RNA 24 weeks after the end of treatment
|
Week 72 (end of follow-up)
|
Number of Patients With a Durable Virologic Response
Time Frame: Week 72
|
Durable Virologic Response (DVR) = below the limit of quantitation in HDV RNA at 24 weeks post-treatment
|
Week 72
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: David Apelian, MD, PhD, MBA, Eiger BioPharmaceuticals
Publications and helpful links
General Publications
- Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, Langer JA, Sheikh F, Dickensheets H, Donnelly RP. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol. 2003 Jan;4(1):69-77. doi: 10.1038/ni875. Epub 2002 Dec 16.
- Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, Ostrander C, Dong D, Shin J, Presnell S, Fox B, Haldeman B, Cooper E, Taft D, Gilbert T, Grant FJ, Tackett M, Krivan W, McKnight G, Clegg C, Foster D, Klucher KM. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol. 2003 Jan;4(1):63-8. doi: 10.1038/ni873. Epub 2002 Dec 2.
- Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol. 2010 Jan;7(1):31-40. doi: 10.1038/nrgastro.2009.205.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EIG-LMD-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis D, Chronic
-
Eiger BioPharmaceuticalsCompleted
-
Gilead SciencesRecruitingChronic Hepatitis D InfectionUnited States
-
Eiger BioPharmaceuticalsAnkara UniversityCompletedChronic Hepatitis D InfectionTurkey
-
Hepatera Ltd.CompletedChronic Hepatitis D Infection
-
Gilead SciencesRecruitingChronic Hepatitis D InfectionAustria, France, Germany, Spain, Romania
-
Shanghai HEP Pharmaceutical Co., Ltd.CompletedChronic Hepatitis D InfectionChina, Mongolia
-
Ziauddin HospitalUnknown
-
Karolinska University HospitalRecruiting
-
University of AthensRecruiting
-
University of Turin, ItalyGilead SciencesRecruiting
Clinical Trials on Peginterferon Lambda-1A
-
Stanford UniversityCompleted
-
Bristol-Myers SquibbCompletedHepatitis CArgentina, Australia, Belgium, France, Germany, Italy, United States, Canada, Spain, Mexico, Austria, Poland, Netherlands, Korea, Republic of, Puerto Rico, New Zealand, Finland, Greece, Romania
-
Bristol-Myers SquibbCompletedChronic Hepatitis C Virus Infection | Chronic Hepatitis B Virus InfectionUnited States
-
Eiger BioPharmaceuticalsActive, not recruitingHepatitis Delta VirusUnited States, France, Belgium, Spain, Italy, Turkey, Bulgaria, Germany, Israel, Romania, Georgia, Moldova, Republic of
-
Icahn School of Medicine at Mount SinaiEiger BioPharmaceuticalsWithdrawnSARS-CoV-2
-
Johns Hopkins UniversityEiger BioPharmaceuticalsTerminatedSars-CoV-2 InfectionUnited States
-
Bristol-Myers SquibbCompletedHepatitis C VirusBelgium, Germany, Spain, United States, Canada, Brazil, Austria, France, Israel, Switzerland, Italy, Russian Federation, Czechia, Poland, United Kingdom
-
University Health Network, TorontoMichael Garron HospitalCompletedCovid-19 | Sars-CoV2Canada, Brazil
-
University Health Network, TorontoActive, not recruitingCovid19 | Sars-CoV2Canada
-
Bristol-Myers SquibbCompletedHepatitis C Virus (HCV)Mexico, Korea, Republic of, Czech Republic